TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31524825

Group type: EXPERIMENTAL
Intervention: MICT (40min at 55‐60% of peak power output, PPO)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HIIT (60 x 8s at 80‐90% of peak heart rate, 12s active recovery)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HIIT + RT (HIIT + 8 whole‐body exercises: 1 set of 8‐12 repetitions)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 27
Study: 27799203

Group type: EXPERIMENTAL
Intervention: ABX464 (50 mg) under fed conditions
Number of subjects: 48

Group type: COMPARATOR
Intervention: ABX464 (50 mg) under fasted conditions
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ABX464 (50 mg)
Number of subjects: 48
Study: 26761561

Group type: EXPERIMENTAL
Intervention: Supervised, moderate-intensity physical exercise (exercise group; EG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Normal daily physical activity (usual group; UG)
Number of subjects: 54
Study: 25196628

Group type: COMPARATOR
Intervention: Traditional marking technique (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: New marking method (Group B)
Number of subjects: 80
Study: 21504485

Group type: EXPERIMENTAL
Intervention: CF101 (2 mg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 19910566

Group type: EXPERIMENTAL
Intervention: bicarbonate-buffered peritoneal dialysis solution (bicPDF)
Number of subjects: 55

Group type: COMPARATOR
Intervention: standard lactate-buffered peritoneal dialysis fluid (SPDF)
Number of subjects: 55
Study: 17488352

Group type: EXPERIMENTAL
Intervention: New algorithm (ICAD)
Number of subjects: 712

Group type: COMPARATOR
Intervention: Standard algorithm (TRODIS)
Number of subjects: 712
Study: 15515332

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bioabsorbable guided tissue regeneration (GTR) barrier (membrane)
Number of subjects: 48
Study: 11373259

Group type: EXPERIMENTAL
Intervention: Group A (n = 109) - seven brief intervention sessions
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Group B (n = 99) - three brief intervention sessions
Number of subjects: 296

Group type: COMPARATOR
Intervention: Control group C (n = 88) - informed of risks and advised to reduce drinking
Number of subjects: 296
Study: 9633727

Group type: EXPERIMENTAL
Intervention: Prednisolone + Azathioprine (PRED + AZA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Prednisolone + Placebo (PRED + PLAC)
Number of subjects: 34
Study: 8150100

Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg two times per day for 9 months)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg for 9 months)
Number of subjects: 20
Study: 2894493

Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Vodka
Number of subjects: 19
Study: 29578097

Group type: EXPERIMENTAL
Intervention: Two doses of HPV vaccine (1-180 days)
Number of subjects: 1795

Group type: COMPARATOR
Intervention: Three doses of HPV vaccine (1-60-180 days)
Number of subjects: 1795
Study: 28688643

Group type: EXPERIMENTAL
Intervention: Lidocaine patch applied around the surgical wound
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with adhesive sides of the lidocaine patches shielded with waterproof films
Number of subjects: 60
Study: 25878309

Group type: EXPERIMENTAL
Intervention: Three-dimensional imaging and templating with standard instrumentation
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Three-dimensional imaging and templating with patient-specific instrumentation
Number of subjects: 46

Group type: COMPARATOR
Intervention: Two-dimensional imaging and standard instrumentation (historical control)
Number of subjects: 46
Study: 22612364

Group type: EXPERIMENTAL
Intervention: 0.3 mg/mL rhPDGF-BB
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 1.0 mg/mL rhPDGF-BB
Number of subjects: 135

Group type: COMPARATOR
Intervention: Scaffold control group
Number of subjects: 135
Study: 20979997

Group type: EXPERIMENTAL
Intervention: Recombinant luteinizing hormone (LH) luteal supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard luteal P protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (Recombinant LH and Standard luteal P protocol)
Number of subjects: 0
Study: 18364502

Group type: EXPERIMENTAL
Intervention: HPV testing (cutoff of 1 pg/mL)
Number of subjects: 49196

Group type: EXPERIMENTAL
Intervention: HPV testing (cutoff of 2 pg/mL)
Number of subjects: 49196

Group type: COMPARATOR
Intervention: Conventional cytology
Number of subjects: 49196
Study: 16293958

Group type: EXPERIMENTAL
Intervention: Nebulized flunisolide (1 mg) + salbutamol/ipratropium bromide (1,875/375 microg) b.i.d.
Number of subjects: 114
Study: 12749746

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study: 15230212

Group type: EXPERIMENTAL
Intervention: 3-phases cardiac rehabilitation program (Study Group, GB)
Number of subjects: 71

Group type: COMPARATOR
Intervention: No participation in phase III of the program (Control Group, GK)
Number of subjects: 71
Study: 10080566

Group type: EXPERIMENTAL
Intervention: D-cycloserine 100 mg/day
Number of subjects: 17
Study: 7744141

Group type: EXPERIMENTAL
Intervention: Zoladex 10.8-mg depot administered every 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zoladex 3.6-mg depot administered every 28 days
Number of subjects: 0
Study: 2405137

Group type: COMPARATOR
Intervention: Control period (6 months) before the initiation of vitamin D therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calculated creatinine clearance (glomerular filtration rate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serum osteocalcin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serum concentrations of alkaline phosphatase, parathyroid hormone, and bicarbonate
Number of subjects: 0
Study: 7390892

Group type: COMPARATOR
Intervention: Split-course irradiation
Number of subjects: 235

Group type: COMPARATOR
Intervention: Continuous-course irradiation
Number of subjects: 235
Study: 31977628

Group type: EXPERIMENTAL
Intervention: 0.04 μg/kg/min norepinephrine infusion
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 0.05 μg/kg/min norepinephrine infusion
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 0.06 μg/kg/min norepinephrine infusion
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 0.07 μg/kg/min norepinephrine infusion
Number of subjects: 99

Group type: COMPARATOR
Intervention: 0 μg/kg/min norepinephrine infusion (control)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Norepinephrine ED50
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Norepinephrine ED80
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Norepinephrine ED95
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Apgar scores or umbilical arterial pH
Number of subjects: 99
Study: 30477937

Group type: EXPERIMENTAL
Intervention: Regorafenib (160 mg/day for 21 of 28 days)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 43
Study: 28342829

Group type: EXPERIMENTAL
Intervention: Intensive peer mentoring (weekly meetings during inpatient stay and weekly contact for 90 days postdischarge)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Intensive peer mentoring
Number of subjects: 158

Group type: COMPARATOR
Intervention: Nonexperimental group (services only on request)
Number of subjects: 158
Study: 25592552

Group type: EXPERIMENTAL
Intervention: CABG with left ventricular reconstruction
Number of subjects: 714

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 714

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 714
Study: 23423576

Group type: EXPERIMENTAL
Intervention: Teplizumab
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 21459838

Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 0

Group type: COMPARATOR
Intervention: Time awake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fast sleep spindles over the left superior parietal cortex
Number of subjects: 0
Study: 18547941

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Volume-cycled Synchronized Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 14
Study: 17387223

Group type: EXPERIMENTAL
Intervention: Yttrium-90 ibritumomab tiuxetan (single dose)
Number of subjects: 104
Study: 15376208

Group type: COMPARATOR
Intervention: Farming population
Number of subjects: 2106

Group type: COMPARATOR
Intervention: Atopic asthma among farmers
Number of subjects: 2106

Group type: COMPARATOR
Intervention: Non-atopic asthma among farmers
Number of subjects: 2106
Study: 12808776

Group type: EXPERIMENTAL
Intervention: High dose oxytocin (starting at 10 mIU/minute)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Low dose oxytocin (starting at 4 mIU/minute)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Both groups (high and low dose)
Number of subjects: 258
Study: 9474311

Group type: EXPERIMENTAL
Intervention: Peribulbar anaesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Retrobulbar anaesthesia
Number of subjects: 40
Study: 7940435

Group type: EXPERIMENTAL
Intervention: Breathing air
Number of subjects: 9

Group type: COMPARATOR
Intervention: Breathing 28% oxygen
Number of subjects: 9
Study: 29447735

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1905

Group type: COMPARATOR
Intervention: PCI
Number of subjects: 1905
Study: 27102726

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low-flow oxygen delivery (Control)
Number of subjects: 36
Study: 25622729

Group type: EXPERIMENTAL
Intervention: Hybrid cycle (voluntary arm exercise combined with FES-induced leg exercise)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Handcycle
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 23052930

Group type: EXPERIMENTAL
Intervention: Home-based virtual cycling training (hVCT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control program
Number of subjects: 27
Study: 22170173

Group type: EXPERIMENTAL
Intervention: Variable flow group (VF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous flow group (CF)
Number of subjects: 40
Study: 18223611

Group type: EXPERIMENTAL
Intervention: DAG
Number of subjects: 7

Group type: COMPARATOR
Intervention: TAG
Number of subjects: 7
Study: 17012095

Group type: EXPERIMENTAL
Intervention: Psycho-education (PE) program (four 60-minute weekly manual driven sessions)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Wait-list (WL) control group
Number of subjects: 67
Study: 14668771

Group type: EXPERIMENTAL
Intervention: SPECT imaging after sublingual administration of 10 mg isosorbide dinitrate
Number of subjects: 36

Group type: COMPARATOR
Intervention: Baseline tetrofosmin SPECT
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SPECT imaging after nitrate administration
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Concordance between tetrofosmin SPECT and PET
Number of subjects: 36
Study: 10907385

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A reconstituted in lidocaine with epinephrine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Botulinum toxin type A reconstituted in saline
Number of subjects: 10
Study: 8601885

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasonography (IVUS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intraarterial digital subtraction angiography (IA DSA) only
Number of subjects: 40
Study: 1279279

Group type: EXPERIMENTAL
Intervention: Isoprenaline (ISO) 1 microgram/min via intravenous infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mepindolol TSD patches
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo TSD patches
Number of subjects: 9
Study: 3905070

Group type: COMPARATOR
Intervention: 2 g cefoxitin i.v. in the preoperative period
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 2 g cefoxitin i.v. in the preoperative period + T tube suction drainage
Number of subjects: 155

Group type: COMPARATOR
Intervention: T tube suction drainage only
Number of subjects: 155
Study: 30517731

Group type: EXPERIMENTAL
Intervention: Mediterranean-Style Eating Pattern with 500 g/wk of lean unprocessed red meat (Med-Red Pattern)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Mediterranean-Style Eating Pattern with 200 g/wk of lean unprocessed red meat (Med-Control Pattern)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mediterranean-Style Eating Pattern (both Med-Red and Med-Control)
Number of subjects: 41
Study: 26947568

Group type: EXPERIMENTAL
Intervention: Outpatient protocol for weaning from tube to oral feeding (6-month program)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 21
Study: 24882900

Group type: EXPERIMENTAL
Intervention: Eszopiclone (ESZ) 3 mg plus naproxen 500 mg BID
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo plus naproxen 500 mg BID
Number of subjects: 52
Study: 22333698

Group type: EXPERIMENTAL
Intervention: MCC‐TT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MCC‐CRM197
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MCC‐TT (after booster)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MCC‐CRM197 (after booster)
Number of subjects: 0
Study: 19798577

Group type: EXPERIMENTAL
Intervention: Circle of Life intervention
Number of subjects: 0
Study: 18319360

Group type: EXPERIMENTAL
Intervention: 15 mg immediate release 3 times daily for 7 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: 45 mg extended release once daily for 7 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 15 mg propiverine intravenously
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 15 mg immediate release administered at night
Number of subjects: 24
Study: 15703362

Group type: EXPERIMENTAL
Intervention: Combination tablet containing lamivudine, stavudine, and nevirapine (treatment A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Separate marketed tablets administered simultaneously (treatment B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination tablet (treatment A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Separate marketed tablets (treatment B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 24
Study: 11990003

Group type: EXPERIMENTAL
Intervention: Protectamin (45 g daily for 2 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Protectamin (45 g daily for 6 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Immunocal (45 g daily for 2 weeks)
Number of subjects: 30
Study: 10418924

Group type: EXPERIMENTAL
Intervention: 1 microg dose of PncT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 microg dose of PncT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 microg dose of PncT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster response to three vaccine serotypes in the group primed with the lowest dose of conjugate vaccine (1 microg)
Number of subjects: 0
Study: 7477168

Group type: EXPERIMENTAL
Intervention: Ritonavir (various dosages)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ritonavir (more sensitive assay in subgroup of 20 patients)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 62
Study: 2147884

Group type: EXPERIMENTAL
Intervention: L-dropropizine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7444552

Group type: EXPERIMENTAL
Intervention: Low-effort (LE) exercise training at 50% of maximal oxygen intake (HR 135 BPM)
Number of subjects: 13

Group type: COMPARATOR
Intervention: High-effort (HE) exercise training at 80% of maximal oxygen intake (HR 170 BPM)
Number of subjects: 13
Study: 31203203

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic surgery
Number of subjects: 768

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 768
Study: 29280722

Group type: EXPERIMENTAL
Intervention: Tailored home modifications
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 92
Study: 26997243

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 153

Group type: COMPARATOR
Intervention: Sham-CPAP
Number of subjects: 153
Study: 24702550

Group type: EXPERIMENTAL
Intervention: Full-time (FT) faculty
Number of subjects: 881

Group type: COMPARATOR
Intervention: Part-time (PT) faculty
Number of subjects: 881
Study: 22521274

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 942

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 942
Study: 20299191

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 0
Study: 18033754

Group type: EXPERIMENTAL
Intervention: Torcetrapib (4 weeks)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Torcetrapib added to atorvastatin (4 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (4 weeks)
Number of subjects: 19
Study: 15830247

Group type: EXPERIMENTAL
Intervention: Simultaneous abscess incision and tooth extraction
Number of subjects: 177

Group type: COMPARATOR
Intervention: Separate abscess incision and tooth extraction
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 177
Study: 12867898

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Uvulopalatopharyngoplasty (UPPP)
Number of subjects: 67
Study: 10577754

Group type: EXPERIMENTAL
Intervention: Intra-articular morphine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of morphine and naloxone
Number of subjects: 21
Study: 8831087

Group type: EXPERIMENTAL
Intervention: Nebulized tobramycin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Baseline oxygen saturation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 12
Study: 1914458

Group type: EXPERIMENTAL
Intervention: Copper-IUD
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-IUD
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inert IUD
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: In vitro experiment with copper-IUD
Number of subjects: 8
Study: 6870623

Group type: EXPERIMENTAL
Intervention: Aminocaproic acid (100 mg/kg every four hours for five days, max 30 g daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (identical regimen to aminocaproic acid)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aminocaproic acid
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 30835505

Group type: EXPERIMENTAL
Intervention: Small-scaled SCUs caring for up to 8 residents, duration 6 months
Number of subjects: 145

Group type: COMPARATOR
Intervention: Large-scaled SCUs caring for 20-30 residents, duration 6 months
Number of subjects: 145
Study: 30928395

Group type: EXPERIMENTAL
Intervention: Total shoulder arthroplasty (TSA)
Number of subjects: 37
Study: 27825616

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg orally daily
Number of subjects: 19
Study: 26397228

Group type: EXPERIMENTAL
Intervention: Sorafenib treatment with low LDH serum levels
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Sorafenib treatment with high LDH serum levels
Number of subjects: 71

Group type: COMPARATOR
Intervention: Chemotherapy without sorafenib
Number of subjects: 71
Study: 23314221

Group type: EXPERIMENTAL
Intervention: Real left DLPFC rTMS
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham left DLPFC rTMS
Number of subjects: 14

Group type: COMPARATOR
Intervention: Naloxone pretreatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline pretreatment
Number of subjects: 14
Study: 20960320

Group type: EXPERIMENTAL
Intervention: ioMRI-guided tumor resection
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional microneurosurgical tumor resection
Number of subjects: 29
Study: 19524577

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion for 72 hours
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo (dextrose) infusion for 72 hours
Number of subjects: 173
Study: 17514187

Group type: EXPERIMENTAL
Intervention: Alprazolam-XR
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alprazolam-CT
Number of subjects: 30
Study: 15213040

Group type: EXPERIMENTAL
Intervention: Dietary inorganic sulfur intake (0.17-0.27 g S/d)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Average protein intake (72 g/d)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Typical UK intakes of inorganic sulfur (0.25 g/d)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Twenty-four-hour urinary nitrogen and sulfate values
Number of subjects: 47
Study: 10971248

Group type: EXPERIMENTAL
Intervention: Heparin-coated group (n = 15; Quadrox Bioline oxygenator/reservoir and Carmeda BioMedicus BP-80 centrifugal pump)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-heparin-coated group (n = 12; uncoated oxygenator, centrifugal pump, tubing, and filter set)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Heparin-coated group (n = 15)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-heparin-coated group (n = 12)
Number of subjects: 27
Study: 8780205

Group type: EXPERIMENTAL
Intervention: Test meal
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic clamping
Number of subjects: 7
Study: 1520018

Group type: EXPERIMENTAL
Intervention: KabiVial 16 IU/ml combined with an Auto Injector
Number of subjects: 30

Group type: COMPARATOR
Intervention: KabiPen 16 IU/ml
Number of subjects: 30
Study: 6386819

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 31522106

Group type: COMPARATOR
Intervention: control with visual feedback
Number of subjects: 60

Group type: COMPARATOR
Intervention: control without visual feedback
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: fatigue with visual feedback
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: fatigue without visual feedback
Number of subjects: 60